Table 3a. Pathological results, with upgrading and upstaging rates highlighted, from radical prostatectomy for patients suitable for the Toronto AS criteria.
| Total (Toronto) | Cambridge | Melbourne | Vancouver | P | |
|---|---|---|---|---|---|
| n | 800 | 280 | 248 | 272 | |
| Pathological GS | |||||
| ⩽ 6 | 395 (47.8%) | 157 (56%) | 94 (38%) | 144 (53%) | <0.001 |
| Upgrading 7 | 389 (48.6%) | 117 (42%) | 151 (61%) | 121 (44%) | |
| 3+4 | 340 (87.4%) | 108 (92%) | 133 (88%) | 99 (82%) | 0.049 |
| 4+3 | 49 (12.6%) | 9 (8%) | 18 (12%) | 22 (18%) | |
| 8–10 | 16 (2%) | 6 (2%) | 3 (1%) | 7 (3%) | |
| pT | |||||
| pT2 | 659 (82.4%) | 205 (73%) | 216 (87%) | 238 (88%) | <0.001 |
| Upstaging | |||||
| pT3/4 | 141 (17.6%) | 75 (27%) | 32 (13%) | 34 (12%) | |
| EPE | 136 (17%) | 73 (26%) | 30 (12%) | 32 (12%) | |
| SVI | 8 (1%) | 2 (1%) | 3 (1%) | 3 (1%) | |
| Margins | |||||
| Negative | 675 (84.4%) | 239 (85%) | 217 (88%) | 219 (81%) | 0.077 |
| Positive | 125 (15.6%) | 41 (15%) | 31 (12%) | 53 (19%) | |
| Percent tumour (n=716) | |||||
| Median | 5 | 5 | 3 | 10 | <0.001 |
| Range | 3–15 | 4–10 | 1.5–9 | 5–20 | |
| Final risk groupa | |||||
| Low | 362 (45.3%) | 135 (48%) | 91 (37%) | 136 (50%) | <0.001 |
| Intermediate | 286 (35.8%) | 65 (23%) | 123 (50%) | 98 (36%) | |
| High | 152 (19%) | 80 (29%) | 13 (13%) | 38 (14%) | |
| CAPRA-S risk groups | |||||
| 0–2 | 629 (78.6%) | 208 (77.9%) | 152 (82.3%) | 143 (75.3%) | 0.42 |
| 3–5 | 165 (20.6%) | 58 (21.7%) | 34 (18.2%) | 44 (23.2%) | |
| ⩾6 | 6 (0.8%) | 1 (0.4%) | 1 (0.5%) | 3 (1.5%) |